MINNEAPOLIS, May 17, 2018 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCMarkets:PETV), (www.petvivo.com) an emerging biomedical device company, is happy to announce that for the first time commercial product is available and the sales force is commencing sales efforts in the form of a soft rollout covering eleven states.
The Kush™ System has been produced, packaged and ready to ship from its production facility and production partner Elite Solutions, in Rochester, Minnesota. Several notable veterinarians that have been involved with the Kush™ System have been waiting months to order. The day has finally come that an extended treatment for Osteoarthrosis for Canine and Equine is available. The company is expecting immediate sales.
Wes Hayne, CEO, stated, “It has taken nearly a year to accomplish the final phases leading up to finished product. Phase I of the rollout is eleven states. We estimate phase II to commence within four to six months adding an additional five states.”
For Phase I, the company has contracted independent distributors covering Minnesota, North Dakota, South Dakota, Wisconsin, Nebraska, Iowa, Kansas, Ohio, Kentucky, Arizona, and New Mexico. Additional markets will be added as the rollout continues. The company is reviewing additional distribution as part of Phase II in Texas, Oklahoma, California, Florida, and New York.
PetVivo is preparing to attend and present at a series of trade shows and veterinarian conferences. Marketing and educational materials are being prepared. Educational material will appear in a couple of weeks on the website which has a major facelift underway. The unveiling of the site should be in 2-3 weeks.
It is a very exciting time for PetVivo Holdings, Inc. We want to continue to thank all our shareholders and associates who have supported us through some very difficult times to this point of celebration.
(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com)
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK:PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
CONTACT:
Wes Hayne
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
Main: 962-405-6216
Direct: (763) 443-7272